2014
Surface-Modified Nanoparticles Enhance Transurothelial Penetration and Delivery of Survivin siRNA in Treating Bladder Cancer
Martin DT, Steinbach JM, Liu J, Shimizu S, Kaimakliotis HZ, Wheeler MA, Hittelman AB, Saltzman W, Weiss RM. Surface-Modified Nanoparticles Enhance Transurothelial Penetration and Delivery of Survivin siRNA in Treating Bladder Cancer. Molecular Cancer Therapeutics 2014, 13: 71-81. PMID: 24222663, PMCID: PMC3924597, DOI: 10.1158/1535-7163.mct-13-0502.Peer-Reviewed Original ResearchConceptsBladder permeability barrierSurvivin siRNAChitosan delivery systemBladder cancerBladder diseaseTherapeutic responseTumor volumeXenograft tumorsMouse bladderTumor siteSurvivin expressionIntravesical deliveryHuman ureterTumor cell uptakeSiRNATumorsUnmodified nanoparticlesCell uptakeDelivery system
2013
Nanoparticles for urothelium penetration and delivery of the histone deacetylase inhibitor belinostat for treatment of bladder cancer
Martin DT, Hoimes CJ, Kaimakliotis HZ, Cheng CJ, Zhang K, Liu J, Wheeler MA, Kelly WK, Tew GN, Saltzman WM, Weiss RM. Nanoparticles for urothelium penetration and delivery of the histone deacetylase inhibitor belinostat for treatment of bladder cancer. Nanomedicine Nanotechnology Biology And Medicine 2013, 9: 1124-1134. PMID: 23764660, PMCID: PMC3815967, DOI: 10.1016/j.nano.2013.05.017.Peer-Reviewed Original ResearchConceptsHistone deacetylase inhibitor belinostatBladder cancerBladder permeability barrierNon-invasive bladder cancerCultured bladder cancer cellsBladder cancer cellsChemotherapy efficacyIntravesical drug deliveryXenograft tumorsMouse bladderMouse modelConvincing dataHuman ureterBelinostatCancerCancer cellsLower IC50TumorsAcetyl-H4Tissue penetrationCLINICAL EDITORIntracellular uptakeDeliveryCellsPatientsA novel polymer-coated nanoparticle (NP) for urothelium penetration and drug delivery.
Hoimes C, Martin D, Kaimakliotis H, Cheng C, Kelly W, Tew G, Wheeler M, Weiss R, Saltzman W. A novel polymer-coated nanoparticle (NP) for urothelium penetration and drug delivery. Journal Of Clinical Oncology 2013, 31: e15543-e15543. DOI: 10.1200/jco.2013.31.15_suppl.e15543.Peer-Reviewed Original ResearchBladder cancerUM-UC-3Human ureterProgression of BCNon-invasive bladder cancerInhibition of invasionHDAC inhibitor belinostatFlank xenograftsTumor sizeDisease progressionTumor regressionUrothelial barrierTumor volumeIntravesical drug deliveryMouse bladderBC cellsHDAC inhibitionMurine bladderCell cytotoxicityT24 lineFACS analysisSimilar IC50Three daysFinal treatmentUreter